Search jobs 10-Jan-2021 Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
–
Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020 –
–
2021 Net Product Revenue Guidance of $950 million to $1,050 million –
– Corporate priorities for 2021 include potentially filing supplemental New Drug Applications for cabozantinib in three additional indications –
– Presentation and webcast at 2021 J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 PM EST / 2:20 PM PST –
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an updat
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Mid Penn Bancorp, Inc. Declares Annual Performance Dividend
Mid Penn BancorpDecember 22, 2020 GMT
MILLERSBURG, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) The Board of Directors of Mid Penn Bancorp, Inc. (“Mid Penn”) (NASDAQ: MPB), the parent company of Mid Penn Bank, at a meeting held on December 22, 2020, declared an annual performance cash dividend of $0.05 per common share, payable January 25, 2021 to shareholders of record as of January 11, 2021.
About Mid Penn Bancorp Inc.
Mid Penn Bancorp Inc. (NASDAQ: MPB), headquartered in Millersburg, Pennsylvania, has been serving the community since 1868. Mid Penn operates retail locations throughout the state of Pennsylvania and has total assets of more than $3 billion. Its footprint includes Berks, Bucks, Chester, Cumberland, Dauphin, Fayette, Lancaster, Luzerne, Montgomery, Northumberland, Schuylkill and Westmoreland counties. The bank of